1 Disclosure 2 Defining Our Terms 3 Meningitis 4 Encephalitis 5 Myelitis 6

1 Disclosure 2 Defining Our Terms 3 Meningitis 4 Encephalitis 5 Myelitis 6

5/5/20 Disclosure Solving Neurologic Mysteries: Next-Generation Approaches to Diagnosis Michael Wilson, MD, MAS Associate Professor UCSF Weill Institute for Neurosciences Department of Neurology Division of Neuroimmunology and Glial Biology 1 2 Defining Our Terms Meningitis • Meningitis: inflammation of the meninges • Encephalitis: inflammation of the brain • Myelitis: inflammation of the spinal cord 3 4 Encephalitis Myelitis 5 6 1 5/5/20 Meningoencephalitis Encephalitis: Morbidity and Mortality • ~20,000 cases/year in the United States • $2 billion in inpatient costs • ~10% mortality • Survivors are frequently disabled – speech, memory, mobility 7 8 Encephalitis of Unknown Etiology Diagnostic Challenges • > 50% unknown cases in 26 of 41 studies in recent meta-analysis • > 100 pathogens cause encephalitis • Not explained by # of pathogens tested for • Wide variation • California Encephalitis Project • Geography • 7 years (1,570 cases): 63% of cases unknown • Season • Patient demographic • Epidemics • Granerod J, et al. Neurology 2010;75:924-932 • Glaser CA, et al. CID 2006;43:1565-1577 9 10 Emerging Neurologic Infections Zika Virus • West Nile virus • Phylogenetic analyses indicate Zika was introduced to BraZil in 2013 • Periodic measles, mumps outbreaks • Chikungunya virus • 18 months before it was detected • Zika virus • Powassan virus • Nearly 2 years before recogniZed as a cause of microcephaly, • Nipah and Hendra viruses meningoencephalitis and Guillain-Barré syndrome • Enterovirus A71 • Chandipura virus • Monkeypox virus • Ebola virus • PML in HIV and other immunosuppressed patients • Rate of severe neurological symptoms caused by emerging viruses • Arenavirus (LCMV-like) in solid organ transplant pts • 39% commonly do so • Dengue virus in the Florida Keys • 10% rarely or occasionally do so • ? SARS-Coronavirus-2 ? • Lipkin WI. Nat Rev Micro 2013;11(2):133-41 • Tyler KL. Arch Neurol. 2009; parts 1 and 2 • Faria NR, et al. Science 2016 11 12 2 5/5/20 Candidate-Based Approach Dubey, et. al. Annals of Neurology, 2018 13 14 Metagenomics NEB Sequencing Library Prep 15 16 NEB Sequencing Library Prep Read-Pairs Retained Time (min) Component Target Four Niches to Fill Raw Sequence 19,574,979 100% 0.0 NA NA (.fastq files) Hg38/PanTro4 Removal of 1,632,130 8.3% 5.2 STAR v2.4.2 RepBase Human Reads • Novel, highly divergent pathogens PriceSeqFilter 816,065 4.1% 5.8 read-pairs Quality Filter v1.1.2 • Pathogens not linked with a clinical phenotype cd-hit-dup Compression of 96,913 0.49% 5.9 read-pairs v4.6.4-2015 • Rare pathogen not on the differential Redundant Reads lzw-filter 92,074 0.47% 6.3 read-pairs • “Rule out” infection in suspected autoimmune cases LZW Complexity (script) Filter bowtie2 Paired-End 2,232 0.01% 6.9 Hg38/RepBase Human Removal v2.2.4 gmap/gsnapl NCBI nt Alignment to 1,683 <0.01% 7.4 v2015-12 2015 nt database rapsearch2 NCBI nr Alignment to 1,467 <0.01% 9.3 v2.23 2015 nr database Taxnomic MySQL NCBI 9.4 Stats/Reporting v5.5.53 Taxonomy Abbreviations: NT, nucleotide; NR, non-redundant protein. 17 18 3 5/5/20 Early Success / Proof Of Concept Early Success / Proof Of Concept Neuroleptospirosis Neuroleptospirosis • Unanticipated bacterial infection • Unanticipated bacterial infection • 48-hour turnaround • 48-hour turnaround • Dramatic clinical improvement • Dramatic clinical improvement Balamuthia mandrillaris • Unanticipated amoebic infection • New cause of endophthalmitis • Wilson MR, et al. NEJM 2014 • Wilson MR, et al. NEJM 2014 • Wilson MR, et al. Ann Neurol 2015 19 20 Early Success / Proof Of Concept Early Success / Proof Of Concept Neuroleptospirosis Neuroleptospirosis • Unanticipated bacterial infection • Unanticipated bacterial infection • 48-hour turnaround • 48-hour turnaround • Dramatic clinical improvement • Dramatic clinical improvement Balamuthia mandrillaris Balamuthia mandrillaris • Unanticipated amoebic infection • Unanticipated amoebic infection • New cause of endophthalmitis • New cause of endophthalmitis • Wilson MR, et al. NEJM 2014 • Wilson MR, et al. NEJM 2014 • Wilson MR, et al. Ann Neurol 2015 • Wilson MR, et al. Ann Neurol 2015 21 22 Early Success / Proof Of Concept Early Success / Proof Of Concept Neuroleptospirosis Cache Valley virus Neuroleptospirosis Cache Valley virus • Unanticipated bacterial infection • New cause of chronic • Unanticipated bacterial infection • New cause of chronic • 48-hour turnaround encephalitis • 48-hour turnaround encephalitis • Dramatic clinical improvement • Undetected spread of an • Dramatic clinical improvement • Undetected spread of an arbovirus to a new continent arbovirus to a new continent Balamuthia mandrillaris Balamuthia mandrillaris • Unanticipated amoebic infection • Unanticipated amoebic infection • New cause of endophthalmitis • New cause of endophthalmitis • Wilson MR, et al. NEJM 2014 • Wilson MR, et al. NEJM 2014 • Wilson MR, et al. Ann Neurol 2015 • Wilson MR, et al. Ann Neurol 2015 • Wilson MR, Suan D, et al. Ann of Neurol 2017 • Wilson MR, Suan D, et al. Ann of Neurol 2017 23 24 4 5/5/20 Early Success / Proof Of Concept Early Success / Proof Of Concept Neuroleptospirosis Cache Valley virus Neuroleptospirosis Cache Valley virus • Unanticipated bacterial infection • New cause of chronic • Unanticipated bacterial infection • New cause of chronic • 48-hour turnaround encephalitis • 48 hour turnaround encephalitis • Dramatic clinical improvement • Undetected spread of an • Dramatic clinical improvement • Undetected spread of an arbovirus to a new continent arbovirus to a new continent Balamuthia mandrillaris Balamuthia mandrillaris Candida dubliniensis • • Unanticipated amoebic infection • Unanticipated amoebic infection Unanticipated fungal • New cause of endophthalmitis • New cause of endophthalmitis infection • Wilson MR, et al. NEJM 2014 • Wilson MR, et al. NEJM 2014 • IV drug use not disclosed • Wilson MR, et al. Ann Neurol 2015 • Wilson MR, et al. Ann Neurol 2015 • Wilson MR, Suan D, et al. Ann of Neurol 2017 • Wilson MR, Suan D, et al. Ann of Neurol 2017 • Wilson MR, O’Donovan B, Gelfand J, et al. JAMA Neurol 2018 25 26 Pitfalls I Pitfalls I • Low input nucleic acid from • Low input nucleic acid from • NGS library kit benchmarking cerebrospinal fluid (picogram cerebrospinal fluid (picogram • Depletion of Abundant Sequences quantities) quantities) by HybridiZation (DASH) • Human background • Human background Figure 3. A Patient 1 Human ChrM (12S +16S) B. mandrillaris 16S 10 0.04 untreated untreated DASHed DASHed age (%) r e v o c m. r no 0 0 500 genomic position 3500 200 genomic position 1200 B Patient 2 Human ChrM (12S +16S) C. neoformans 18S 10 1.2 untreated untreated DASHed DASHed age (%) r e v o c m. r no 0 0 500 genomic position 3500 350 genomic position 550 C Patient 3 Human ChrM (12S +16S) T. solium 18S 18 12 untreated untreated DASHed DASHed age (%) r e v o c m. r no 0 0 500 genomic position 3500 500 genomic position 2500 • Gu W, Crawford ED, O’Donovan B, Wilson MR, et al. Genome Biol 2016 • Ramani V, Shendure J. Genome Biol 2016 27 28 Pitfalls II Pitfalls II • Environmental contamination • Environmental contamination • Weighted Z score-based scoring algorithm to separate bona fide pathogen sequences for spurious environmental sequences • Wilson MR*, O’Donovan B*, Gelfand J*, et al. JAMA Neurol 2018 29 30 5 5/5/20 Case 1 Case 1 • 40 year-old physician with 15 years of relapsing myelitis and • 40 year-old physician with 15 years of relapsing myelitis and arachnoiditis arachnoiditis • Evaluated and treated at top academic medical centers • Evaluated and treated at top academic centers • Immigrated to US from India at age 22; lived in AZ, NY and MD • No history of intravenous drug use • No known animal, mosquito or tick exposures • Beck E, et al. Ann Neurol 2019 • Beck E, et al. Ann Neurol 2019 31 32 Case 1 Case 1 • 2002: Subacute onset of back pain and malaise -> night sweats, fever, anorexia, severe headache and neck stiffness • CSF • WBC 454 (25% lymphocytes, 15% neutrophils, 60% monocytes) • Protein 96 • Glucose 23 33 34 Case 1 Case 1 • Treated for tuberculous meningitis for 3 months (had to stop due to • Treated for tuberculous meningitis for 3 months (had to stop due to medication side effects) medication side effects) • 2006: epidural anesthesia for childbirth -> Temp 102F, headache, neck stiffness, back pain, night sweats -> got antibiotics • …but low-grade symptoms for months before acute onset bilateral gluteal and left leg pain 35 36 6 5/5/20 Case 1 Case 1 • CSF • Significant improvement but intermittent low back pain and chills • WBC 130 (83% lymphocytes, 2% neutrophils, 13% monocytes) • Glucose 10 • Protein 132 • Laminectomy at L5-S1 for biopsy -> non-specific inflammation • 1 more year of anti-tuberculosis therapy 37 38 Case 1 Case 1 • Significant improvement but intermittent low back pain and chills • Since May 2015 has been on >35 mg of daily prednisone plus… • 2015: days after thyroid surgery developed low back and leg pain and • Mycophenolate mofetil (up to 3000mg daily) for 8 months numbness with chills, headache, fever and neck stiffness • Methotrexate (Jan 2017 to present) • Given valacyclovir + prednisone with dramatic improvement • Chronic, dull aching pain in back and buttocks that worsens with • Recurrent symptoms when steroids tapered sitting, bending or twisting or moving her head • Monthly gets general malaise, Temp 101F and more severe throbbing pain for 1-2 weeks 39 40 Case 1 Cysticercosis • CSF • Taenia solium tapeworm • RBC 156 • Two intermediate hosts • WBC 30 (92% lymphocytes,

View Full Text

Details

  • File Type
    pdf
  • Upload Time
    -
  • Content Languages
    English
  • Upload User
    Anonymous/Not logged-in
  • File Pages
    14 Page
  • File Size
    -

Download

Channel Download Status
Express Download Enable

Copyright

We respect the copyrights and intellectual property rights of all users. All uploaded documents are either original works of the uploader or authorized works of the rightful owners.

  • Not to be reproduced or distributed without explicit permission.
  • Not used for commercial purposes outside of approved use cases.
  • Not used to infringe on the rights of the original creators.
  • If you believe any content infringes your copyright, please contact us immediately.

Support

For help with questions, suggestions, or problems, please contact us